Hepatitis B Virus Infection in Diffuse Large B-Cell Lymphoma Patients
Author Information
Author(s): Wang Feng, Xu Rui-hua, Luo Hui-yan, Zhang Dong-shen, Jiang Wen-qi, Huang Hui-qiang, Sun Xiao-fei, Xia Zhong-jun, Guan Zhong-zhen
Primary Institution: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, PRoC
Hypothesis
HBV might play an important role in the development of B-cell NHL, and that the HBsAg-positive B-cell NHL patients could be considered a clinically distinct subgroup.
Conclusion
HBsAg-positive DLBCL patients had earlier onset and more advanced stage, with significant prognostic factors being disease stage and hepatic dysfunction during chemotherapy.
Supporting Evidence
- HBsAg-positive DLBCL patients had a younger median onset age compared to HBsAg-negative patients.
- More advanced disease stages were observed in HBsAg-positive patients.
- Hepatic dysfunction was significantly more common in HBsAg-positive patients before and during chemotherapy.
- The overall survival rates at 3 years were 48% for patients with hepatic dysfunction and 72% for those with normal liver function.
Takeaway
This study found that patients with hepatitis B virus infection who have lymphoma tend to get sick earlier and have more severe disease, which can affect their treatment.
Methodology
Retrospective analysis of DLBCL patients divided into HBsAg-positive and HBsAg-negative groups, with various statistical analyses performed.
Potential Biases
Potential biases due to the retrospective nature of the study and the small sample size of certain subgroups.
Limitations
The study is retrospective and may have biases related to patient selection and treatment protocols.
Participant Demographics
262 DLBCL patients, with 81 HBsAg-positive and 181 HBsAg-negative; median age of HBsAg-positive group was 46 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI of 23.5-70 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website